Amprius Grew Revenue 83% in Q3, Yet the Stock Fell 7.5%: Why

Amprius Technologies grew third-quarter revenue 83% year over year to $39.1 million, raised its full-year revenue guidance to roughly $145 million, and still watched its stock fall more than 7.5% in after-hours trading. The drop reflects a headline miss of one penny per share against expectations, not a deterioration in the underlying business. The company is a battery maker in the middle of a capacity ramp, and ramps consume cash before they return it.

The numbers behind the quarter tell a story of scaling rather than stalling. Revenue of $39.1 million beat the consensus estimate by about 9%, driven by improving demand across aerospace, drones, defense and mobility. Gross margin expanded by roughly 12 percentage points to 27%, the clearest sign yet that scale is starting to work in the company's favor.

What did the company tell investors about 2025 and 2026?

Management lifted its revenue guidance to approximately $145 million for the full year, about 3% above the consensus at the time of the report. Several factors suggest that forecast may prove conservative.

• U.S. revenue grew 2.3 times sequentially as domestic demand surged.
• Demand is shifting toward products compliant with the National Defense Authorization Act (NDAA).
• The SiCore 500, launched in September, delivers higher energy density, commands premium pricing, and draws interest from aviation and unmanned vehicle manufacturers.
• Management has a track record of conservative forecasts.

The picture for 2026 is more mixed. Amprius cut its 2026 adjusted EBITDA guidance from more than $4 million to at least $2.5 million, because it is increasing spending to support growth. Management still expects a GAAP net loss for 2026. The takeaway is straightforward: revenue is compounding faster than expected, but profitability has been pushed further out by deliberate investment.

How does the balance sheet support the ramp?

Amprius made a strategic pivot away from building its own manufacturing facility toward contract manufacturing. That asset-light approach reduced the capital spending required to expand production, and the Q3 balance sheet shows the benefit.

The company held nearly $61 million in cash against $7.8 million in quarterly operating cash burn. Receivables, current assets and total assets all rose, while liabilities declined. Equity grew by about 20%, and the company carries no debt. In plain terms, the company has enough cash to fund its ramp for several quarters at the current burn rate without borrowing.

What do analysts expect for the stock?

Fourteen analysts contribute to a Moderate Buy consensus rating, with an 85% buy-side tilt. The consensus price target sits at $20.50 against a share price of $8.69, implying roughly 130% upside. The high forecast is $33.00 and the low is $14.00. The stock trades in a 52-week range of $7.02 to $24.23.

The Q3 release may not trigger dramatic estimate revisions, but analysts see it as sufficient to keep the group constructive. Coverage has been improving, and sentiment heading into the report was broadly positive.

Two structural risks temper that view. Institutions own only about 5% of the stock, although recent filings show meaningful buying activity. Short interest stands at 16%, high enough that a positive surprise could force a rapid repricing, but also high enough to keep pressure on the shares until a catalyst arrives.

Where do the next catalysts come from?

The near-term catalysts center on a $75 million Department of Defense contract awarded recently. Executing on that contract unlocks milestone awards while advancing Amprius toward NDAA compliance. The company expects to achieve full NDAA compliance with domestically produced cells in 2027.

On the capacity side, Amprius plans to upgrade its U.S. production line to handle up to 12 million cells annually by early 2028. New contracts could follow over the next four quarters as the company advances toward compliance, and those contracts could feed future revenue growth.

Without a fresh catalyst, the stock may drift, and the next scheduled one may not arrive until the Q4 release in early 2027. High short interest at 16%, however, sets up conditions for a sharp advance once a trigger appears.

Is the sell-off a buying opportunity?

The initial after-hours drop of more than 7.5% narrowed as trading continued, which suggests the market reconsidered the headline miss. Fear remains dominant in this name: investors sold first and asked questions later. The fundamental story, on the reported numbers, remains intact.

Technical indicators support that read. Moving average convergence divergence (MACD) and stochastic indicators align with strong support and a broader market reversal. The stock could hold support near its early November lows, build a base, and then reverse. MACD convergences suggest a retest of existing highs is possible in the near to mid term.

The longer-term case depends on execution rather than technicals. Amprius must expand production, convert the defense contract into milestone payments, and reach sustained profitability before the market rewards it fully. If the company delivers on its 12-million-cell domestic line and its 2027 compliance target, the current guidance of roughly $145 million in revenue may look, as analysts suspect, like a floor rather than a ceiling.